Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
762.980.17%
QQQ
722.050.08%
BTC/USD
81021.440.2525%
DIA
516.150.05%
GLD
401.490.08%
TLT
81.260.01%

Dianthus Therapeutics Inc

DNTHNASDAQ
Trade with Public
Trade with Public
$96.81
-4.31-4.26%
At close: Sep 18, 5:00 PM EST
$96.81
N/A
After Hours: Sep 18, 4:07 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Dianthus Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Dianthus Therapeutics (DNTH).

Price Target Range — 13 Quarters

Analyst Consensus — 18 Analysts

1S.Buy
17Buy
Consensus RatingBuy# Analysts18Avg. Consensus PT$129Upside to Avg. PT+33.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 11, 2026JP MorganBrian ChengInitiateOverweight$135
Sep 4, 2026CitigroupSamantha SemenkowInitiateBuy$156
More with Benzinga EdgeGet Access

Analyst Ratings News

This Shopify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Wall Street analysts initiated coverage on PPG, Shopify, Chesapeake Utilities, Global Payments and Dianthus, with targets ranging from $101 to $160.
Avi Kapoor

PRO
JP Morgan Initiates Coverage On Dianthus Therapeutics with Overweight Rating, Announces Price Target of $135

JP Morgan analyst Brian Cheng initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Overweight rating and announces Price Target of $135.
Benzinga Newsdesk

PRO
Citigroup Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $156

Citigroup analyst Samantha Semenkow initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $156.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $128

Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $110 to $128.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $158

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $130 to $158.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $122

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $105 to $122.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved